Article
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A…
Cancer Management and Research · 2023 · Kim Y, Yamamoto S, Kato K
Key facts
| Title | Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data |
|---|---|
| First author | Kim Y, Yamamoto S, Kato K |
| Journal | Cancer Management and Research |
| Published | May 10, 2023 |
| DOI | 10.2147/CMAR.S390499 |
| Devices mentioned | K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186, K854187 and 1 more |
| Product codes mentioned | CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, KLB, KLS and 1 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1